ZakAria® (Pembrolizumab)

ZakAria is a humanized monoclonal antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.ZakAria® (Pembrolizumab) is used alone or in combination with other medicines to treat certain types of cancer including:

• Skin cancer (Melanoma and Merkel cell carcinoma)
• Lung cancer
• Head and neck cancer
• Certain types of lymphoma (Hodgkin and large B-cell)
• Cancer of the kidney, bladder, and urinary tract
• Colorectal cancer
• Liver cancer
• Breast cancer
• Cancer of the cervix or uterus
• Advanced stomach or esophageal cancer